RYTM RHYTHM PHARMACEUTICALS, INC.

8-K Current Report

Filed: March 16, 2026

Health Care

Pharmaceutical Preparations

RHYTHM PHARMACEUTICALS, INC. (RYTM) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• EMANATE trial topline results disclosed — binary readout event; clinical outcome directly drives near-term valuation and pipeline de-risking
• Results delivered via press release and investor presentation — full data accessible in accompanying exhibits for detailed efficacy/safety metrics

+1 more insights

Item 8.01 · Other Events

• EMANATE trial failed all four primary endpoints; none of the four genetic substudies achieved statistical significance (all p-values >0.05)
• Post hoc LOCF analyses showed significant BMI reductions in POMC/PCSK1 Hets (–5.5%, p=0.0010) and SRC1 (–6.2%, p<0.0001) — but post hoc data is hypothesis-generating, not regulatory-grade evidence

+3 more insights

Other RHYTHM PHARMACEUTICALS, INC. 8-K Filings

8-K Mar 2, 2026

8-K Feb 26, 2026

Get deeper insights on RHYTHM PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.